Skip to main content

Advertisement

SpringerLink
Log in

Guillain-Barré syndrome after short-course efalizumab treatment

  • Letter to the editors
  • Published:
Journal of Neurology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Caproni M, Volpi W, Chiarini C, Antiga E, Giomi B, Fabbri P (2009) A case of natural killer cell monoclonal expansion during efalizumab treatment in a patient with psoriasis. Br J Dermatol 160:896–897

    Article  CAS  PubMed  Google Scholar 

  2. Kuehn BM (2009) Efalizumab withdrawn. JAMA 3101:2085

    Google Scholar 

  3. Miller FW, Hess EV, Clauw DJ, Hertzman PA, Pincus T, Silver RM, Mayes MD, Varga J, Medsger TA, Love LA (2000) Approaches for identifying and defining environmentally associated rheumatic disorders. Arthritis Rheum 43:243–249

    Article  CAS  PubMed  Google Scholar 

  4. Press R, Ozenci V, Kouwenhoven M, Link H (2002) Non-T (H) 1 cytokines are augmented systematically early in Guillain-Barré syndrome. Neurology 58:476–478

    CAS  PubMed  Google Scholar 

  5. Stubgen JP (2008) Tumor necrosis factor-alpha antagonists and neuropathy. Muscle Nerve 37:281–292

    Article  CAS  PubMed  Google Scholar 

  6. van Doorn PA, Ruts L, Jacobs BC (2008) Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome. Lancet Neurol 7:939–950

    Article  PubMed  Google Scholar 

  7. Victor F, Menon K, Latkowski JA, Fernandez-Obregon A, Strober BE (2008) Efalizumab-associated Guillain-Barre syndrome. Arch Dermatol 144:1396–1397

    Article  PubMed  Google Scholar 

Download references

Conflict of interest statement

The authors report no competing interests.

Author information

Authors and Affiliations

  1. Department of Neurological and Visual Sciences, University of Verona, Piazzale Scuro 10, 37100, Verona, Italy

    Marco Turatti, Stefano Tamburin & Maria Luigia Praitano

  2. Section of Neurology, Pederzoli Hospital, Via Monte Baldo 24, Peschiera del Garda, 37019, Verona, Italy

    Marco Turatti, Stefano Tamburin, Domenico Idone, Maria Luigia Praitano & Giampietro Zanette

Authors
  1. Marco Turatti
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stefano Tamburin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Domenico Idone
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Maria Luigia Praitano
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Giampietro Zanette
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stefano Tamburin.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Turatti, M., Tamburin, S., Idone, D. et al. Guillain-Barré syndrome after short-course efalizumab treatment. J Neurol 257, 1404–1405 (2010). https://doi.org/10.1007/s00415-010-5521-8

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00415-010-5521-8

Keywords

Search

Navigation